

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### Efficacy Evaluation of Loaded Nanostructured Lipid Carriers (NLC) with Luliconazole in Treatment-Resistant Dermatophytosis

#### Protocol summary

##### Study aim

Determining the effect of nanostructured lipid carriers (NLCs) loaded with luliconazole on patients with treatment-resistant dermatophytosis.

##### Design

The first group: patients with treatment-resistant dermatophytosis, and non-onychomycosis, who will receive itraconazole, will be the control group. The second group: patients with treatment-resistant dermatophytosis, not onychomycosis, who will receive NLC gel drug loaded with luliconazole. The third group: patients with treatment-resistant dermatophytosis, non-onychomycosis, who will receive NLC gel drug loaded with luliconazole and itraconazole.

##### Settings and conduct

The current research is a clinical trial study that will be conducted on 75 patients with treatment-resistant dermatophytosis who were referred to the Baghban (Tubi) specialized clinic and skin and beauty clinics in Sari City during the years 1403-1404. The study is single-blind, so patients will not know the type of medicine they receive.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: patients with treatment-resistant dermatophytosis Exclusion criteria: children, neonates, and individuals who took the drugs in the last week.

##### Intervention groups

After diagnosis by a specialist, patients with dermatophytosis are identified through clinical and laboratory methods, including history of treatment. The study includes common antifungals like terbinafine. After confirming terbinafine-resistant cases, patients will be grouped according to the protocol and prescribed the appropriate medication. Patients will receive medicine for two weeks.

##### Main outcome variables

Complete recovery of clinical symptoms Negative mycological criteria: negative result in direct examination or culture

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20240711062393N1**

Registration date: **2024-07-25, 1403/05/04**

Registration timing: **prospective**

Last update: **2024-07-25, 1403/05/04**

Update count: **0**

##### Registration date

2024-07-25, 1403/05/04

##### Registrant information

##### Name

Mahdi Abastabar

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 11 3321 7501

##### Email address

mabastabar@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2024-08-10, 1403/05/20

##### Expected recruitment end date

2024-11-10, 1403/08/20

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Efficacy Evaluation of Loaded Nanostructured Lipid Carriers (NLC) with Luliconazole in Treatment-Resistant Dermatophytosis

#### Public title

Efficacy Evaluation of Nano-Luliconazole in Patients with Treatment-Resistant Dermatophytosis

#### Purpose

Treatment

#### Inclusion/Exclusion criteria

##### Inclusion criteria:

patients with treatment-resistant dermatophytosis

##### Exclusion criteria:

Neonates and children range from 0 to 19 years  
pregnant mothers

#### Age

From **20 years** old

#### Gender

Both

#### Phase

1

#### Groups that have been masked

- Participant

#### Sample size

Target sample size: **75**

More than 1 sample in each individual

Number of samples in each individual: **75**

The first group, patients with treatment-resistant dermatophytosis and non-onychomycosis, who will receive itraconazole, will be the control group. The second group consists of patients with treatment-resistant dermatophytosis, without onychomycosis, who will be receiving the NLC gel drug loaded with luliconazole. The third group consists of patients with treatment-resistant dermatophytosis, and non-onychomycosis who will receive NLC gel drug loaded with luliconazole and itraconazole.

#### Randomization (investigator's opinion)

Randomized

#### Randomization description

randomization The block method will be used for randomization. This will be performed using Random allocation software. To ensure unpredictability, the software will calculate block number and size. Based on numbers produced by the software, samples are assigned to groups.

#### Blinding (investigator's opinion)

Single blinded

#### Blinding description

Simultaneously, the participants receive information regarding conducting a research study and complete the consent form; however, the type of luliconazole gel (simple or nano form) will remain concealed from her.

#### Placebo

Not used

#### Assignment

Factorial

#### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Mazandaran University of Medical Sciences

##### Street address

Moalem square

##### City

Sari

##### Province

Mazandaran

##### Postal code

4817844718

#### Approval date

2024-05-14, 1403/02/25

#### Ethics committee reference number

IR.MAZUMS.REC.1403.048

## Health conditions studied

### 1

#### Description of health condition studied

Dermatophytosis is an inflammatory skin infection caused by dermatophyte fungi including Trichophyton, Microsporum, Epidermophyton, Lophophyton, Nannizzia, Parathion, and Arthroderma.

#### ICD-10 code

B35

#### ICD-10 code description

Dermatophytosis

## Primary outcomes

### 1

#### Description

individuals with treatment-resistant dermatophytosis

#### Timepoint

Patients are evaluated after 2 and 4 weeks of treatment.

#### Method of measurement

Assessing improvement, lesion size, itch, and inflammation based on the questionnaire's scoring.

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Intervention group: The first group includes patients resistant to dermatophytosis other than onychomycosis

who take NLC gel loaded with luliconazole.

### Category

Treatment - Drugs

## 2

### Description

Intervention group: The second intervention group: patients resistant to dermatophytosis other than onychomycosis also receive itraconazole along with luliconazole.

### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

کلینیک تخصصی باغبان (طوبی) و کلینیک باران شهرستان ساری

##### Full name of responsible person

Ghasem Rahmatpour Rokni

##### Street address

Sari, 15 Khordad, 30 meter Valiasr Street, Valiasr Street, Valiasr Street, 15 Khordad Street

##### City

Sari

##### Province

Mazandaran

##### Postal code

4818865475

##### Phone

+98 11 3325 0450

##### Email

Dr.rokni@yahoo.com

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Mazandaran University of Medical Sciences

##### Full name of responsible person

Alireza Rafiei

##### Street address

Moalem square

##### City

Sari

##### Province

Mazandaran

##### Postal code

4817844718

##### Phone

+98 11 3448 4804

##### Email

pajhooeshi@mazums.ac.ir

##### Grant name

##### Grant code / Reference number

##### Is the source of funding the same sponsor organization/entity?

Yes

### Title of funding source

Mazandaran University of Medical Sciences

### Proportion provided by this source

100

### Public or private sector

Public

### Domestic or foreign origin

Domestic

### Category of foreign source of funding

empty

### Country of origin

### Type of organization providing the funding

Academic

## Person responsible for general inquiries

### Contact

#### Name of organization / entity

Mazandaran University of Medical Sciences

#### Full name of responsible person

Mahdi Abastabar

#### Position

Associate professor

#### Latest degree

Ph.D.

#### Other areas of specialty/work

Mycology

#### Street address

Sari, Imam Square (RA) - Juibar Road, the beginning of Valiasr Highway (AJ), Mazandaran University of Medical Sciences

#### City

Sari

#### Province

Mazandaran

#### Postal code

۴۸۱۵۷۳۳۹۷۱

#### Phone

+98 11 3304 4000

#### Email

mabastabar@gmail.com

## Person responsible for scientific inquiries

### Contact

#### Name of organization / entity

Mazandaran University of Medical Sciences

#### Full name of responsible person

Mahdi Abastabar

#### Position

Associate professor

#### Latest degree

Ph.D.

#### Other areas of specialty/work

Mycology

#### Street address

Sari, Imam Square, Juibar road, the beginning of Valiasr roadway, Mazandaran University of Medical Sciences

#### City

Sari  
**Province**  
Mazandaran  
**Postal code**  
۴۸۱۵۷۳۳۹۷۱  
**Phone**  
+98 11 3304 4000  
**Email**  
ravabetomoomi@mazums.ac.ir

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Mazandaran University of Medical Sciences  
**Full name of responsible person**  
Mahdi Abastabar  
**Position**  
Associate professor  
**Latest degree**  
Ph.D.  
**Other areas of specialty/work**  
Mycology  
**Street address**  
Sari, Imam square, Juibar road, The beginning of  
Valiasr, Mazandaran University of Medical sciences  
**City**  
Sari  
**Province**  
Mazandaran  
**Postal code**  
4815733971  
**Phone**  
+98 11 3304 4000  
**Email**  
mabastabar@gmail.com

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

### Study Protocol

Yes - There is a plan to make this available

### Statistical Analysis Plan

Yes - There is a plan to make this available

### Informed Consent Form

Yes - There is a plan to make this available

### Clinical Study Report

Yes - There is a plan to make this available

### Analytic Code

Yes - There is a plan to make this available

### Data Dictionary

Yes - There is a plan to make this available

### Title and more details about the data/document

Contributors' data in the study is shareable once it is unidentifiable.

### When the data will become available and for how long

The access period begins six months after the results are published.

### To whom data/document is available

researchers who are working at universities

### Under which criteria data/document could be used

This information is only for comparison with similar research."

### From where data/document is obtainable

"The information provided is only intended for comparison with similar research."

### What processes are involved for a request to access data/document

Project data sets will be housed on the Web site and/or the file transfer protocol site created for the study, and all data sets will be password-protected. Project Principal Investigators will have direct access to their own site's data sets, and will have access to other sites' data by request. To ensure confidentiality, data dispersed to project team members will be blinded of any identifying participant information

### Comments